human
papillomaviru
hpv
infect
common
sexual
transmit
diseas
worldwid
hpv
oncogen
small
doublestrand
dna
virus
primari
causal
agent
cervic
cancer
type
cancer
includ
anu
oropharynx
vagina
vulva
peni
prophylact
vaccin
hpv
attract
strategi
prevent
cervic
cancer
type
cancer
howev
safe
effect
vaccin
hpv
infect
current
firstgener
commerci
hpv
vaccin
expens
produc
deliv
goal
studi
develop
altern
potent
hpv
recombin
vaccin
produc
hpv
viruslik
particl
vaccin
current
use
worldwid
live
attenu
measl
viru
mv
vaccin
wellestablish
safeti
efficaci
record
recombin
mv
rmv
produc
revers
genet
may
use
gener
candid
hpv
vaccin
meet
need
develop
world
studi
nonhuman
primat
rmvvector
hpv
vaccin
parallel
classic
alum
adjuv
recombin
protein
vaccin
produc
pichia
pastori
combin
primeboost
approach
use
vaccin
evalu
well
immun
interfer
due
preexist
immun
mv
humor
immun
respons
induc
mv
pichiaexpress
vaccin
combin
prime
boost
approach
found
elicit
specif
total
igg
neutral
antibodi
titr
preexist
antibodi
measl
prevent
immun
respons
persist
infect
sustain
highrisk
genotyp
human
papilloma
virus
hpv
lead
develop
highgrad
squamou
intraepitheli
lesion
ultim
caus
cervic
cancer
cc
worldwid
approxim
cc
caus
serotyp
remain
caus
least
highrisk
hpv
subtyp
major
capsid
protein
hpv
capabl
selfassembl
viruslik
particl
vlp
typespecif
highli
immunogen
antigen
elicit
high
titr
neutral
antibodi
confer
protect
hpv
infect
current
prophylact
hpv
vaccin
base
structur
protein
well
establish
prevent
cc
two
licens
hpv
vaccin
quadrival
gardasil
merck
vaccin
kenilworth
nj
usa
bival
cervarix
form
glaxosmithklin
vaccin
brentford
uk
approv
mani
countri
found
safe
effect
prevent
infect
vaccinerel
hpv
serotyp
howev
administr
virtual
nonexist
develop
countri
mainli
prohibit
high
cost
http
elsevi
ltd
right
reserv
abbrevi
hpv
human
papilloma
viru
cc
cervic
cancer
mv
measl
viru
rmv
recombin
mv
ez
edmonston
zagreb
strain
ifn
interferon
gamma
interleukin
ic
concentr
give
respons
halfway
baselin
maxim
n
nucleocapsid
protein
p
phosphoprotein
matrix
protein
f
fusion
protein
h
attach
protein
nnsv
nonseg
neg
strand
rna
viru
vaccin
difficulti
implement
vaccin
program
requir
three
inject
adolesc
girl
sixmonth
period
recent
approv
nonaval
vaccin
gardasil
merck
provid
protect
addit
oncogen
type
hpv
howev
possess
difficulti
predecessor
therefor
nextgener
hpv
vaccin
requir
reduc
product
cost
improv
immun
schedul
feasibl
studi
aim
develop
costeffect
safe
effect
prophylact
hpv
vaccin
address
need
develop
countri
develop
recombin
hpv
vaccin
base
live
attenu
measl
viru
mv
vector
platform
addit
compar
immun
respons
classic
pichia
pastorisproduc
recombin
vaccin
nonhuman
primat
live
attenu
mv
vaccin
wellestablish
safeti
efficaci
record
inexpens
produc
deliv
develop
countri
mv
vaccin
induc
lifelong
immun
singl
inject
revers
pathogen
never
observ
estim
global
immun
coverag
least
first
dose
live
attenu
mv
vaccin
higher
mv
envelop
viru
nonseg
negativesens
singlestrand
rna
genom
nucleotid
length
genom
contain
six
transcript
unit
separ
nontranscrib
trinucleotid
intergen
sequenc
flank
leader
trailer
sequenc
genom
end
mev
genom
encod
total
eight
protein
six
structur
protein
nucleocapsid
protein
n
phosphoprotein
p
matrix
protein
fusion
protein
f
attach
protein
h
larg
rnadepend
rna
polymeras
protein
l
two
addit
nonstructur
protein
c
v
encod
p
transcript
unit
recombinantmv
rmv
produc
revers
genet
repres
attract
platform
gener
multival
vaccin
immun
measl
infecti
agent
carri
therapeut
agent
proof
concept
mv
use
express
antigen
deriv
hiv
hepat
b
west
nile
viru
sar
coronaviru
chikungunya
viru
studi
rmv
express
heterolog
antigen
appear
induc
longterm
specif
neutral
antibodi
even
presenc
preexist
immun
mv
previou
studi
vaccin
candid
found
effect
induc
specif
neutral
antibodi
transgen
mice
suscept
mv
infect
examin
develop
recombin
live
attenu
mv
edmonstonzagreb
rmvez
strain
viral
vector
carri
heterolog
gene
encod
major
capsid
protein
rhesu
monkey
compar
immunogen
tradit
methylotroph
p
pastorisbas
express
system
humancodon
optim
gene
code
antigen
chemic
synthes
geneart
tm
thermo
fisher
scientif
usa
plasmid
p
mvez
deliv
correctli
ribozymetermin
mv
antigenom
construct
previous
describ
bsshiiaatii
clone
synthet
gene
addit
transcript
unit
posit
p
protein
gene
p
mvez
fig
method
use
clone
similar
describ
sambrook
russel
ligat
product
transform
escherichia
coli
stratagen
usa
ultra
compet
cell
grow
coloni
select
ampicillin
lgml
resist
screen
bsshiiaatii
digest
miniprepar
plasmid
dna
follow
qiagen
plasmid
purif
protocol
recombin
posit
clone
name
p
p
use
transform
cell
amplifi
maxiprepar
follow
qiagen
plasmid
purif
protocol
assay
analyt
digest
confirm
primerwalk
sequenc
eurofin
mwg
biotech
germani
virus
rescu
cell
transfect
fiveplasmid
transfect
system
singl
syncytia
expand
cell
line
establish
passag
recombin
virus
serial
passag
prepar
suffici
viru
stock
rmvezhpv
quantifi
microtitr
plate
spearman
karber
formula
media
cell
lysat
vero
cell
infect
either
lyse
h
postinfect
analyz
sdspage
determin
express
hpvspecif
antigen
western
blot
detect
specif
mous
monoclon
antibodi
abcam
uk
genetex
usa
qdot
western
blot
kit
thermo
fisher
scientif
yeastcodon
optim
transgen
assembl
de
novo
synthesi
geneart
tm
thermo
fisher
scientif
clone
bstbinoti
new
england
biolab
ipswich
usa
ppicza
express
vector
thermo
fisher
scientif
control
promot
method
use
clone
similar
describ
sambrook
russel
obtain
plasmid
propag
e
coli
select
zeocin
lgml
thermo
fisher
scientif
resist
linear
saci
digest
use
transform
electrocompet
p
pastori
methanol
induct
cell
lyse
acidwash
glassbead
mm
lysi
buffer
mm
sodium
phosphat
mm
pmsf
mm
edta
glycerol
centrifug
clarifi
supernat
protein
express
clone
confirm
sdspage
reduc
condit
western
blot
specif
mous
monoclon
antibodi
abcam
master
work
cell
bank
prepar
yeast
pepton
dextros
media
wherea
routin
product
batch
produc
chemic
defin
synthet
media
batch
ferment
substag
cell
induc
methanol
protein
express
batch
harvest
pellet
lyse
highpressur
homogen
kpsi
clarifi
clarifi
lysat
load
onto
cation
exchang
resin
purifi
antigen
sterilefilt
lm
filter
final
concentr
store
assess
vlp
format
purifi
protein
neg
stain
uranyl
acet
examin
electron
microscop
rmvezhpv
viru
stock
store
thaw
stock
mix
obtain
test
bival
measl
hpv
vaccin
inject
within
h
purifi
recombin
protein
prepar
aluminum
phosphat
adjuv
mgml
final
pb
aqueou
formul
final
concentr
antigen
lgml
lgml
vaccin
adsorb
overnight
fill
quantiti
mlvial
store
experi
nonhuman
primat
subject
thorough
physic
veterinari
examin
clinic
biochemistri
paramet
examin
healthi
rhesu
monkey
immun
ml
vaccin
formul
per
anim
equival
one
human
dose
tabl
moreov
assess
immun
respons
elicit
rmvezhpv
vaccin
formul
case
preexist
immun
mv
includ
anim
alreadi
immun
vaccin
dose
attenu
measl
vaccin
boost
dose
rmvezhpv
inject
booster
pichia
express
hpv
wherea
given
group
tabl
bleed
done
day
sera
collect
subsequ
analysi
elisa
plate
precoat
overnight
ngwell
purifi
protein
next
day
plate
wash
remov
unbound
protein
plate
block
skim
milk
pbst
h
wash
pbst
sera
sampl
dilut
pbst
maintain
h
wash
antisimian
igg
label
horseradish
peroxidas
ad
incub
h
wash
tmb
substrat
ad
incub
min
dark
plate
read
nm
spectramax
micropl
reader
molecular
devic
usa
one
known
posit
sera
sampl
use
standard
dilut
serial
paramet
logist
regress
curv
fit
test
sampl
titrat
evalu
determin
absolut
antibodi
titr
extrapol
curv
higher
neg
control
pb
titr
increas
defin
seroconvers
measur
specif
antihpv
neutral
antibodi
vitro
pseudovirusbas
neutral
assay
pbna
conduct
use
secret
alkalin
phosphatas
seap
report
monkey
sera
assay
either
pool
individu
sampl
test
reagent
materi
cell
line
report
gene
plasmid
pyseap
well
method
pseudoviru
psv
product
neutral
obtain
john
schiller
laboratori
cellular
oncolog
nci
nih
bethesda
md
usa
produc
lipofectamin
transfect
cell
harvest
purifi
optiprep
gradient
tabl
experiment
studi
design
anim
per
test
group
anim
pb
prime
day
boost
except
pichia
express
hpv
boost
either
intramuscular
im
subcutan
sc
administr
shown
ultracentrifug
sigma
usa
seap
detect
cell
cultur
supernat
use
great
escap
seap
chemiluminesc
detect
kit
clontech
usa
accord
manufactur
instruct
use
multilabel
plate
reader
perkin
elmer
usa
neutral
titr
defin
reciproc
highest
dilut
serum
reduc
seap
activ
least
compar
reactiv
control
well
receiv
psv
antibodi
sera
least
neutral
activ
score
neutral
data
statist
analyz
use
graphpad
prism
softwar
determin
half
maxim
inhibitori
concentr
valu
describ
previous
sera
sampl
twofold
dilut
mem
fb
analyz
microtitr
plate
live
attenu
mvez
viru
equival
per
per
well
ad
except
cell
control
well
vero
cell
seed
cell
per
well
per
cell
growth
media
mem
fb
incub
co
incub
day
cell
observ
measlesspecif
cytopath
effect
cpe
invert
microscop
record
reciproc
last
dilut
neutral
sera
sampl
determin
absenc
cpe
consid
endpoint
titr
statist
signific
differ
data
set
determin
use
twotail
student
ttest
oneway
nonparametr
analysi
varianc
use
graphpad
prism
softwar
window
anim
experi
perform
accord
nation
anim
ethic
guidelin
govern
india
approv
institut
anim
ethic
committe
cadila
healthcar
ltd
ahmedabad
india
select
recombin
plasmid
respect
name
p
p
fig
verifi
analyt
digest
primer
walk
sequenc
mwg
biotech
germani
use
transfect
cell
rescu
correspond
attenu
virus
supplementari
fig
rescu
virus
amplifi
use
cell
grew
effici
parent
viru
reach
titr
higher
moreov
rmvezhpv
express
high
stabl
level
antigen
subsequ
passag
fig
show
western
blot
character
select
viru
bestexpress
clone
select
base
sdspage
western
blot
profil
confirm
also
electron
microscopi
vlp
format
rang
size
nm
irregular
shape
supplementari
fig
b
primat
vaccin
hpv
vaccin
alon
differ
combin
variou
test
group
pb
neg
control
tabl
measl
contain
vaccin
immun
subcutan
rout
sc
pichia
express
protein
vaccin
immun
intramuscularli
im
humor
immun
respons
induc
vaccin
suscept
primat
comparison
p
pastori
express
hpv
vaccin
total
igg
respons
measur
antibodi
elisa
antibodi
titr
fig
b
higher
pb
neg
control
titr
earli
dose
vaccin
group
antibodi
titr
slightli
increas
booster
group
variou
interv
immun
end
experiment
anti
titr
alway
higher
neg
control
interestingli
one
dose
mv
vector
hpv
vaccin
given
measl
vaccineprim
anim
antihpv
antibodi
appear
quickli
later
result
confirm
preexist
immun
measl
interfer
replic
mv
vector
hpv
vaccin
addit
prime
pichia
boost
measl
hpv
result
increas
titr
demonstr
classic
nextgener
measl
hpv
combin
immun
notabl
nextgener
measl
vector
hpv
vaccin
show
antibodi
titr
compar
differ
interv
end
studi
similar
classic
pichia
express
hpv
vaccin
fig
b
demonstr
measl
vector
classic
pichia
express
vaccin
induc
remark
level
hpvspecif
neutral
antibodi
fig
b
antibodi
titr
appear
earli
dose
vaccin
group
wherea
titr
detect
titr
boost
dose
maintain
high
level
end
experi
antibodi
titr
consist
rel
lower
fig
antibodi
respons
total
igg
titr
measur
elisa
b
total
igg
titr
measur
elisa
figur
repres
antihpv
igg
antibodi
titr
elicit
monkey
group
immun
test
vaccin
differ
time
interv
statist
signific
differ
titr
group
determin
oneway
nonparametr
analysi
varianc
p
consid
statist
signific
signific
calcul
respect
pb
neg
control
group
neutral
antibodi
measur
figur
repres
antihpv
neutral
antibodi
titr
elicit
monkey
group
immun
test
vaccin
differ
time
interv
statist
signific
differ
titr
group
determin
oneway
nonparametr
analysi
varianc
p
consid
statist
signific
signific
calcul
respect
pb
neg
control
group
notesera
test
pool
anti
neutral
therefor
statist
signific
calcul
figur
repres
antimeasl
neutral
antibodi
titr
elicit
monkey
group
immun
test
vaccin
differ
time
interv
statist
signific
differ
titr
group
determin
oneway
nonparametr
analysi
varianc
p
consid
statist
signific
signific
calcul
respect
measl
alon
group
antimeasl
neutral
antibodi
respons
induc
measl
vector
vaccin
compar
commerci
measl
vaccin
immun
fig
thu
titr
induc
measl
affect
incorpor
hpv
transgen
demonstr
measl
vector
use
measl
immun
vector
antigen
main
goal
studi
establish
evalu
nextgener
measl
vector
rmvezhpv
vaccin
rmvezhpv
vaccin
found
compar
classic
pichia
express
hpv
vaccin
shown
immun
profil
term
gener
hpv
total
igg
neutral
antibodi
relat
cellular
immun
respons
nonhuman
primat
measl
vector
hpv
vaccin
show
titr
level
higher
compar
neg
control
igg
neutral
antibodi
level
compar
classic
pichia
express
hpv
vaccin
group
cost
effect
rmvezhpv
vaccin
better
vaccin
produc
market
leader
gardasil
cervarix
vaccin
cost
vari
countri
develop
countri
gardasil
cost
approxim
per
dose
cervarix
commerci
hpv
vaccin
offer
develop
countri
measl
vaccin
cost
approxim
offer
unicef
price
commerci
hpv
vaccin
requir
complet
threedos
vaccin
regimen
confer
protect
immun
therefor
vaccin
fulfil
need
hpv
vaccin
develop
countri
lowresourc
area
process
vaccin
product
complex
involv
numer
step
seed
batch
ferment
lysi
clarif
chromatographi
ultracentrifug
andor
ultrafiltr
steril
filtrat
adjuv
adsorpt
fill
use
yeast
classic
recombin
express
system
baculoviru
contrast
live
measl
vaccin
produc
quickli
simpli
use
cell
viru
propag
roller
bottl
follow
harvest
supernat
clarif
blend
final
fill
lyophil
yield
live
viru
measl
hpv
quit
high
approxim
dose
per
batch
roller
bottl
yield
yeastbas
hpv
vaccin
product
lower
approxim
dose
l
batch
therefor
cost
produc
live
attenu
measl
vector
hpv
vaccin
much
lower
yeast
recombin
protein
vaccin
moreov
titr
alway
lower
studi
howev
common
hpv
vaccin
thu
titr
obtain
vaccin
also
support
strongweak
antigen
paradigm
antigen
gener
balanc
desir
level
immun
respons
test
two
differ
antigen
deliveri
system
either
alon
combin
use
heterolog
prime
boost
approach
found
compar
result
term
total
igg
neutral
antibodi
titr
differ
vaccin
group
therefor
vaccin
combin
use
field
alreadi
commerci
avail
vlp
vaccin
furthermor
verifi
effect
preexist
immun
measl
antihpv
immun
respons
recombin
vaccin
candid
administ
booster
mvhpv
vaccin
mvprime
anim
observ
signific
increas
titr
postboost
thu
individu
preimmun
titr
measl
also
vaccin
hpv
also
extens
safeti
record
live
viral
vaccin
includ
measl
prove
nonseg
neg
strand
rna
viru
nnsv
genet
exchang
safeti
concern
could
theoret
risk
pose
nnsv
genet
exchang
alreadi
exist
natur
creat
use
live
vaccin
inde
vaccin
strain
restrict
infect
replic
capac
particip
dual
infect
wild
viru
necessari
genet
exchang
data
obtain
immunogen
studi
encourag
find
provid
foundat
develop
novel
costeffect
prophylact
hpv
vaccin
rmvezhpv
vaccin
induc
high
titr
neutral
antibodi
nonhuman
primat
reduct
either
neutral
antibodi
titr
measl
product
yield
compar
parent
strain
clinic
trial
approach
plan
author
actual
potenti
conflict
interest
includ
financi
person
relationship
amongst
organ
submit
work
work
submit
publish
previous
except
form
abstract
part
publish
lectur
academ
thesi
electron
preprint
consider
public
elsewher
public
approv
author
work
develop
hpv
new
candid
vaccin
provid
cadila
healthcar
ltd
ahmedabad
india
etna
biotech
ltd
catania
itali
